Introduction
Gene therapy represents the introduction of genetic material into cells for therapeutic purposes. The recent scientific breakthroughs in the genomics field and the important role of genes in different diseases have made gene therapy one of the most rapidly evolving fields of biotechnology, with great promise for treating both inherited and acquired diseases. As for today, gene therapy represents the ultimate method of protein delivery, in which the delivered gene enters the body's cells and turns them into small 'factories' that produce a therapeutic protein for a specific disease over a prolonged period of time. Many human diseases are caused by mutations in specific genes, leading to lack of expression of the corresponding protein or expression of abnormal protein. Through genetic engineering and recombinant DNA technology it is possible to isolate such genes, and further administer them to patients in order to compensate their absence.
As gene therapy has moved from the laboratory into the clinic, three issues have emerged as central to the development of this technology: gene identification, gene expression and gene delivery. The gene therapy products can be classified based on the basis of their delivery system being viral or nonviral vectors. 1 Even though the manufacturing of these vectors can be analogous to that used for recombinant DNA products or vaccine, there are some unique challenges due to the evolving analytical methodology for characterizing these types of products that are still being developed. For example, the traditional assays used to quantify viral dose, such as the plaque assay or the tissue culture infectious dose assay, are able to detect only a small fraction of the active vector particles, the precision of these assays being about a factor of three (half a log). Also, specific risks associated with the direct administration of different gene therapy products to patients, which could have as an outcome a modification of the gene expression pattern and deregulation of the cells have to be addressed by extensive preclinical studies and quality control testing that need to be developed in accordance with the applicable regulations. We hereby provide an overview on the various regulatory considerations required to be followed when validating an assay procedure in compliance with GLP (Good Laboratory Practice) and cGMP (current Good Manufacturing Practice). Also, few bioanalytical methods, PCR, enzyme-linked immunospot (ELISPOT) assay, Microarrays and Limulus Amebocyte Lysate (LAL) test, have been selected for discussion.
Validation requirements
Validation of an assay represents a process where the suitability of an analytical procedure is demonstrated for the intended application. Validation of an assay consists of analysing or verifying eight or nine assay parameters as described in the ICH guidelines [2] [3] [4] (International Conference of Harmonisation, having as a primary scope the harmonisation of the pharmaceutical legislative framework between Europe, Japan and USA). Within a validation process, the performance characteristics of an assay are studied by extensive laboratory testing of different validation parameters like specificity, linearity, range, accuracy, precision, detection limit, quantification limit and robustness, thus providing information about the possible errors, likelihood of their occurrence and their quantification within the method.
A comprehensive validation consists of a huge amount of testing and laboratory work. To ease the load of the work, some part of the validation can be initiated already from the optimisation phase of an assay. For example, when designing a PCR analysis, the rationale for selecting and designing the primers and/or probes is provided during the development phase of the assay, while the specificity of the primers and/or probes is tested during the optimisation phase.
For routine tests (eg DNA concentration and particle number determinations) also trend data from positive controls and/or reference standards can be used for evaluating the repeatability of the assay or establishing the criteria for outliers, with the condition that enough replicates have been analysed. However, one should remember that no trend data alone would be sufficient to demonstrate the above-mentioned parameters, but it could be indicative for following-up the assay performance and further used to complete the specific validation package as required within regulatory submissions.
A few principles are good to keep in mind when proceeding towards an assay validation: (1) qualified laboratory personnel; to minimize the variation due to an operator, the personnel should be well trained and qualified for the specific task, (2) validated and qualified equipment; to ensure the performance of the laboratory equipments, (3) know your assay; the person who is designing a validation plan for an assay should be familiar with the specific characteristics of the assay, its strengths and weaknesses. It is preferable that this person has been involved already in the development and optimisation of the assay.
As a general rule, all analyses related to the manufacturing (GMP, Table 1 .), preclinical (GLP) and clinical (GCP) studies should be validated in accordance with the current applicable regulatory requirements.
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Evolution of an assay
Prior to its implementation in the current laboratory practice, an assay has to proceed through different phases from its development to its final validation (Figure 1) . The most suitable conditions for performing the assay are studied during the optimisation phase after which a preliminary validation is performed that enables the establishment of the specific criteria for the actual validation and thorough evaluation of the characteristics of the assay planned to be validated.
Once an assay is validated for its intended purpose, also the revalidation policy needs to be established. The revalidation of an assay represents a process where either a specific part or a complete validation is repeated due to particular reasons such as predetermined revalidation schedules, failing of one or two parameters in a validation followed by reoptimisation of the method, changes are made in the manufacturing process, product or analytical procedure including also equipment and/or software changes.
As a general rule, assays need to be validated or revalidated:
Before their introduction into routine use Whenever the conditions change for which the assay has been validated, for example, instrument with different characteristics Whenever the method is changed, and the change is outside the original scope of the method Assay development begins as soon as the product is available. The requirements for an assay performance are changing when evolving from a different product developmental phase to another. For example in preclinical and Phase I studies, it may be acceptable to have qualitative or semiquantitative methods like agarose gel electrophoresis for analysing different plasmid isoforms, 
Validation parameters
When designing an assay validation plan, particular attention should be given to the intended purpose of the assay by defining the critical parameters that need to be validated.
The specific definitions of the assay validation parameters are briefly described below: Specificity (or selectivity) is a parameter, which describes the ability of an assay to measure an analyte in a sample in the presence of other components, which are expected to be present in the sample (eg impurities, degradants, matrix). Linearity describes the ability of an assay to elicit results, which are directly, or by a well-defined mathematical transformation, proportional to the concentration of an analyte in a sample. Range of a method is the area between the lower and upper limit of quantification, which follows linearity and where the method has been demonstrated to be accurate and precise. Accuracy is the measure of exactness of an analytical method or the closeness of agreement between the measured value and the value that is accepted as a conventional true value or an accepted reference value. Recovery describes the amount of an analyte, which is present in the sample after sample preparation steps (eg extraction). It can be also associated with the sampling efficiency. Precision represents the closeness of agreement (degree of scatter) between a series of measurements obtained from multiple sampling of a homogeneous sample under prescribed conditions. It is expressed as a relative standard deviation (RSD), which is obtained by dividing the standard deviation (SD) with the mean of the analyte value (concentration or amount). Precision can be divided in three levels: repeatability, intermediate precision and reproducibility. Repeatability (intra-assay precision) measures the variation of multiple determinations of a single sample in a single test run, whereas intermediate precision (interassay precision) measures the variation of multiple determinations of a single sample, controls and reagents analysed in several assay runs. Reproducibility, however, measures the precision between laboratories and it is usually measured in collaborative studies or in case of standardization of an analytical procedure, for example, for inclusion within pharmacopoeial procedures. Limit of detection (LOD) is the lowest amount of an analyte in a sample that can be distinguished from the background, but not necessarily quantified as an exact value. Limit of quantification (LOQ) is the lowest amount of an analyte in a sample, which can be quantified with acceptable accuracy and precision. Robustness measures the capacity of an assay to remain unaffected by small, but deliberate changes in method parameters giving an indication of the reliability of the method under normal usage. The parameters tested within robustness typically include the stability and quality of the sample and analytical solutions (eg antibody and detection solutions, pH and conductivity, variation in serums from different species), changes in analytical conditions (eg incubation times and temperatures), the cell passage number, variation between different patients and variation due to the equipments (eg use of different electrodes and columns).
The selection of the validation parameters and their requirements depend on the nature and type of the analytical method. In pharmaceutical guidelines, a rough distribution has been done between identification, content, potency, dissolution and impurity/other tests (quantitative and qualitative assays), as described in Table 2 .
The purpose of an identification analysis is to ensure the identity of the analyte, which means that the assay needs to elicit absolute specificity. For example, in restriction enzyme digestion analyses, which are generally used as identification assays of plasmid DNA products, the enzymes should be selected in a way that no other DNA plasmid, which is handled in the laboratory, has the same restriction digestion pattern with the used enzymes as the analyte.
In purity and content analyses, the ability of an assay to measure the selected parameter in the presence of other substances present in the sample should be demonstrated by the specificity. This means that the influence of the interfering factors, which might be present in the sample, should be evaluated. For example, in an endotoxin test using the LAL, high amount of DNA may result in false positive results and therefore the 'safe' amount of DNA, which can be present in the sample, has to be evaluated by titration. In other cases when the specificity of an assay cannot be demonstrated, like in the OD 260 measurement of DNA, the validity and Validation overview of bio-analytical methods M Tuomela et al the accuracy of the assay need to be justified by excluding the presence of interfering substances (RNA, proteins and chromosomal DNA) by other purity analyses combined with the determination of the absorbance ratio A 260/280 measurement.
Once the specificity has been demonstrated, the linearity can be tested from the calibration curve using a pure analyte or by analysing spiked samples. If the data needs to be transformed to demonstrate the linearity, the simplest mathematical model should be used. The obtained signals (or signal/concentrationresponse factor) are plotted against the concentration of the analyte and the results are analysed with appropriate statistical method (eg regression analysis). For the analyses, where a statistical method cannot be applied, the concentration-response relationship should represent the adequate accuracy and precision throughout the analytical range.
The determination of accuracy usually requires 'a golden standard' or an accepted method to which a new method can be compared. The most common problems are encountered when no golden standard or other accepted methods are available for comparison. In these cases, the accuracy can be tested by analysing real samples, which are spiked with known quantities of an analyte.
As biological assays often include preliminary sample extraction steps, the recovery of the analyte should be determined especially when the specific assay is for the release analysis of the product. Well-designed spiking studies, where the amount of analyte is measured before and after the extraction, are relatively easy to carry out. The amount of the analyte after extraction does not need to be 100% but it should be consistent and repeatable.
When evaluating the precision, the extent of testing depends on the circumstances under which the analytical procedure is intended to be used. Usually at least the repeatability and the intermediate precision between different days and operators should be evaluated. In some special cases, also other variables can be taken into account like different equipments, columns, etc. The reproducibility is usually included in the validation only when transferring an analytical procedure or when applying the same standard operating procedure and methodology in separate laboratories. The acceptable variation is dependent on the nature and classification of the assay as well as on the requirements set in the product specifications (Table 3) .
Usually the LOD is determined for qualitative assays or limit tests, for example for qualitative PCR application and identification analyses, and the LOQ for quantitative assays, for example for impurity analyses, where low levels of analyte have to be detected in the sample matrix. It may not be reasonable to determine the LOQ in assays, where large amounts of analyte are detected, for example in assays for the content of the active substance. The LOD and LOQ can be tested in a similar way, and if needed, at the same time, even though the LOD does not necessarily need to be determined if the LOQ is included. For qualitative methods or limit tests, the LOD can be established only visually, thus setting up the lowest limit empirically. For quantitative methods, where the linearity is tested, it is recommended that the LOD and/or LOQ are calculated using the specific equations from the regression line or, if the method exhibits a baseline noise, by calculating it from the signal-to-noise ratio. When reasonable, also other statistical methods can be applied like the Poisson's distribution.
The LOD is the point at which a measured value is larger than the uncertainty associated with it. It is the lowest concentration of an analyte in a sample that can be detected but not necessarily quantified. In chromatography, the LOD is the injected amount that results in a peak with a height of at least twice or three times as high as the baseline noise level. The LOQ is the minimum injected amount that gives precise measurements, in 
+ Signifies that this characteristic is normally evaluated.
(+) Signifies that this characteristic is only optionally evaluated. À Signifies that this characteristic is not normally evaluated. ). The calculated RSD% of the precision is plotted against the analyte amount. The amount that corresponds to the previously defined required precision is equal to the LOQ.
Robustness examines the effect that operational parameters have on the analysis results and it is recommended to be evaluated during the development/ optimisation phase of an assay, but not required to be included as part of a registration application. 3 For the determination of the robustness of an assay, a number of chromatographic parameters, for example flow rate, column temperature, injection volume, detection wavelengths or mobile phase composition, are varied within a realistic range and the quantitative influence of the variables is determined. If the influence of the parameter is within a previously specified tolerance, the parameter is said to be within the robustness range of the method. Obtaining data on these effects will allow to judge whether a method needs to be revalidated, if one or more parameters are changed, for example to compensate for column performance over time.
Even after the validation, the precision and accuracy of the assay should be monitored regularly to ensure that the assay performs satisfactory. One way of monitoring is to include a system suitability test within the assay procedure. For example, the use of positive (and negative) controls or standards, spiked with known amount of analytes, that will enable to follow the performance of the assay. To justify the assay validity, the positive and negative control and/or standard samples should meet the preset requirements for the final result and the variation between replicate sample preparations.
Applying the validation
A laboratory applying a specific assay should have documented evidence that the method has been appropriately validated. The responsibility remains with the user to ensure that the validation is documented to meet the requirements for the specific method. If standard methods (American Society for Testing and Materials, International Organization for Standardization, European and US Pharmacopoeias) are used, it should be verified that the scope of the method and validation data, for example sample matrix, linearity, range and detection limits, comply with the laboratory analysis requirements. Otherwise, the validation of the standard method should be repeated using the laboratory's own criteria. The laboratory should demonstrate the validity of the method in the laboratory's environment. Complete validation of a standard method is recommended where no information on type and results of validation can be found in standard method documentation. There are no official guidelines on the sequence of validation experiments and the optimal sequence can depend on the method itself.
Within this chapter, we provide an overview of the critical parameters recommended to be included as part of a validation package for PCR, ELISPOT, Microarray and LAL assays, which have been selected as being representative examples of molecular biological, immunological and microbiological assays used in the analysis and development of gene therapy products and vaccines.
PCR assays
The target tissues, persistence and clearance (biodistribution) of the investigational product should be studied as part of the preclinical safety studies. For gene therapy products, the biodistribution can be studied by screening the tissues for the therapeutic DNA sequence using a PCR methodology.
PCR technique 7, 8 enables a specific in vitro amplification of DNA and RNA (RT-PCR) segments. The double-stranded template DNA is denatured into singlestranded DNA, after which two synthetic oligonucleotide primers of different orientation bind to the complementary sequences on the template DNA. Short doublestranded regions, limited by the primers, are amplified by heat-stable DNA polymerase. By repeating these denaturation-annealing-elongation steps up to 30-40 times, millions of copies of the selected sequence can be amplified as little as from one copy of the target sequence.
Owing to its high sensitivity, PCR assay is prone to crosscontamination and false positive results unless proper precautions are taken into consideration such as dividing the work in separate areas depending on the analysis step, use of protecting clothing, separate pipettes and filter tips as well as the use of uracyl-Nglycosylase-sensitive amplicons to prevent the carryover contamination. 9 Negative and so-called sentinel controls, which mimic the sample, should be used for controlling contamination. Standardized procedures established for preventing contamination may help to demonstrate the specificity and reliability of the assay.
The sampling is the first critical issue for the PCR analysis. For example, the environment for collecting the samples and the order in which the samples are collected may be critical, for example, in biodistribution studies, where the animals are injected with the plasmid DNA product the risk for crosscontamination is high. Also some anticoagulants, like heparin, used for collecting the blood may inhibit PCR reactions. The biological samples, included within a PCR analysis require that the template for the PCR needs to be extracted and purified before analysis. The efficiency and reproducibility of the extraction and purification procedures should be demonstrated in spiking studies where samples are spiked both prior to and after extraction.
As the specificity of a PCR method depends on the choice and quality of the primers and probes, as well as on the reaction conditions and detection, the rationale for the selection of the primer and probe sequences should be carefully justified. It is important to be aware of possible interfering substances and PCR inhibitors, such as those present in the sample matrix or other plasmid DNA products, which are handled in the same laboratory and might cause a risk for crosscontamination. The quantification method and chemistry (eg SYBR Green versus fluorescent probes) as well as the quantification standards should be selected carefully to obtain specific and accurate quantification. These standards should have the same amplification efficiency as the study samples. Positive controls should be carried out in each PCR run to follow the performance of the assay.
The specificity of a PCR assay can be demonstrated by assessing the resulting PCR product by gel Validation overview of bio-analytical methods M Tuomela et al electrophoresis, thus confirming that the amplicon is of expected size or by melting curve analyses, as well as by analysing different templates, which could be present in the PCR reaction as a contamination or as a sample matrix, like chromosomal DNA. The linearity of the assay should be demonstrated throughout the intended range and a crossing point (or sample concentration) should be represented as a function of the obtained fluorescence/ fluorescence ratio. The accuracy may be inferred once the linearity and the precision from run to run and between multiple operators have been demonstrated.
The LOD (or positive cutoff) and LOQ of a PCR assay are usually tested empirically by analysing several replicate dilutions of the target template and they are represented as a number of target sequences per sample amount. The LOD can be determined to be the concentration, which can be detected in 95% of runs, and the LOQ, respectively, the minimum number of target sequences that can be detected and quantified in all runs. Parameters, which influence on the LOD and LOQ of a PCR assay, include the distribution of the target sequence in the sample and the performance of the assay, for example, repeatability, pipetting errors, quality of reagents, homogeneity of the reaction conditions and distribution of the reaction mixture in a PCR tube (splashes).
ELISPOT assay
ELISPOT assays 10, 11 are often used to measure the T-cell responses in different vaccine immunogenicity and efficacy studies. T cells isolated from the blood are stimulated with different antigens in order to induce cytokine synthesis and/or secretion, such as IFN-g, which is used especially in monitoring of CD8-specific CTL or CD4-specific Th 1 responses. [12] [13] [14] The produced IFN-g is then bound onto a solid membrane, which is coated with a specific monoclonal antibody. The bound IFN-g is then detected using sandwich enzyme-linked immunosorbent assay (ELISA) technique. 15 The IFN-g-secreting cells are detected as colour spots on the membrane, each spot representing one single cell producing IFN-g, the number of the spots being proportional to the strength of the immune response. Other ELISPOT assays for IL-2 (Th 1 response), IL-4 (Th 2 response) or Perforin (direct cytotoxic response) are also available and in use.
Even though the ELISPOT method provides a quantitative measurement of the spots and immune response, the quantification differs completely from the traditional standard curve using assays. ELISPOT is a typical biological assay measuring the responses of living cells in vitro. Therefore, already the sample sets specific requirements, which need to be optimized accordingly.
Samples from different individuals, who have different strengths of immune response, are analysed. At different time points of blood harvesting also the same individual can respond differently. Special care should be taken in evaluating the results of individuals having different immunological disorders such as HIV-infected patients whose T-cell composition may vary due to the treatment and progress of the infection. For example, Smith et al 13 showed that a depletion of CD4 cells resulted in a loss of signal with some mitogens in IFN-g ELISPOT assay. Handling blood samples and living cells requires special attention with respect to the storage time and conditions, which are crucial for the assay performance. The time interval from blood harvesting until the separation of PBMC has a major influence on the cell viability and performance of the assay. Cell culturing procedures should be standardized and optimized with respect to the starting amount of the viable cells, reagents and incubation times as well as the titration and composition of antigens and peptides used for stimulating the cells. To achieve the best signal-to-noise ratio, the antibody capture and detection steps should be optimized including all the washing steps (efficiency of manual wash versus automatic washer), the amount of coating and detection antibodies, as well as the incubation times and conditions. Each assay should contain negative and positive controls (eg PHA, tetanus toxoid, FEC) to demonstrate the assay validity. Positive controls should exist for the stimulation as well as for the antibody capture/detection (ELISA).
The robustness of the sample handling and storage should be demonstrated, as it is the first and most critical parameter influencing the assay performance and reliability of the results. The influence of storage conditions (including the sample container), freezing-thawing cycle and different storage times should be evaluated. The linearity of the assay should be demonstrated by studying the response as a function of the viable cells used for the stimulation. The variation within each step of the analytical procedure, PBMC separation, cell culture, ELISA and spot counting steps (also human versus computer count when they are used) should be evaluated separately. An evaluation of the variation in the response obtained from blood samples collected from the same individual at different time points could provide valuable information about the possible variability caused by the sample. The limit of quantification is established by determining the lowest response, which can be reliably quantified as spot-forming cells (SPC). One should also set limits for the response, which is interpreted as a 'positive' or a significant result when evaluating the potency or efficiency of a 'pharmaceutical product'.
Gene expression analysis
The functionality of gene therapy products is dependent on expression and targeting of the therapeutic gene. Several methods exist for analysing gene expression in vivo and in vitro such as ELISA, 15 Northern 16 and Western blot, 17 RT-PCR 8 and DNA Microarrays. 18 The efficiency of the expression and the target tissues are often studied either with vectors containing a gene encoding a fluorescent protein, such as luciferase 19 and/or green fluorescent protein (GFP), 20, 21 combined with the therapeutic gene or replacing it.
In ELISA and Western blot assays, the expressed protein is usually analysed directly from serum or tissue samples, whereas in Northern blot, RT-PCR and Microarrays the analysis is preceded by the extraction of mRNA (or total RNA) from animal tissues. In fluorescent protein assays, the signal is detected usually from formaline-fixed, paraffin-embedded tissues or tissue extracts. The principles concerning the handling and storage of biological samples should be taken into account. The Microarrays, as a powerful method for screening the expression of genes, have become recently a very popular tool among the researchers.
A Microarray can be thought as a refined Southern blot assay, which includes a PCR step; the cDNA probe is Whether the platform is selected, the biological variation between individuals and different targeted gene populations may cause variation in the array results and thus may hinder their interpretation especially in the cases where it is difficult to identify the cause of the variation as being either due to the technical reasons, natural biological variation or a real result. Therefore, the repeatability from array to array should be demonstrated in respective of both biological and technical variation and the accuracy of the results should be confirmed by comparing it with other methodologies like Northern blot or RT-PCR. As in traditional hybridization assays, the critical steps causing the technical variation are the hybridization (eg ratio of the probes and sample/control ratio and the purity of the RNA sample), the efficiency of the cDNA amplification and labelling, washing and reading. Positive and negative controls should be used to control the sample quality and the technical performance of the array. Special attention should be provided to the selection of the genes or the software used for the normalization of the raw data as well as on the statistical method used for evaluating the data. An International Society, Microarray Gene Expression Data (MGED), has been established to help all microarray scientists to obtain and compare reliable data by aiming to establish standards for the data annotation as well as a common database, which enables the sharing of the data in the field of functional genomics and proteomics. As a result, the requirements for minimum information about a microarray experiment (MIAME) have been set to facilitate the interpretation of the microarray results 23 and are recommended to be followed when designing a new array.
LAL test the Gel-Clot method
As an example of a microbiological test, we discuss the Limulus Amebocyte Lysate (LAL) test, which is used for bacterial endotoxin determination. Among other microbiological tests, for example sterility test, mycoplasma, adventitious viruses and replication competent viruses related tests, the determination of the bacterial endotoxin level within a product belongs to the critical safety analyses required by regulatory authorities to be included as part of the battery of tests used for the final product release. Compared to the conventional pyrogen testing, which uses rabbits as an animal model, 24 ,25 the LAL is much more convenient to perform also from the ethical point of view.
The test uses an LAL representing the blood, which is extracted from a horseshoe crab (Limulus polyphemusor, Tachypleus tridentatus). When incubated with the lysate, the endotoxin present in the sample triggers an enzymatic reaction path, resulting in an activation of the lysate coagulase and finally formation of a firm white gel. If the gel is not formed, the sample contains less endotoxin as has been specified for the lysate sensitivity. When positive results are obtained, the actual amount of endotoxin present in the sample is determined by analysing serial dilutions of the sample. 26, 27 The LAL has been approved in European 27 and US Pharmacopoeias 26 as a standard method, which are describing also the validation part. The most critical parts to be validated for an LAL assay are the interfering factors, which are recommended to be evaluated for each new type of sample material used within the assay, and the maximum valid dilution (MVD) that should be used for each particular sample. The interfering factors should be removed for example by dilution, filtration, neutralization or heating. For example, DNA at high concentrations is known to enhance the reaction in a Gel-Clot method and thus causing false positive results. Therefore, the concentration at which the enhancement does not occur should be tested empirically by testing different dilutions of the sample.
Conclusions
As a conclusion, the extent and requirements for the assay validation depend on the developmental phase of the assay and the product for which the assay is applied. The validation policies, also for the revalidation, should be defined already at the beginning of the product development. There are often critical issues to consider also in the sampling and sample handling of biological materials as well as in the study design to enable the reliable interpretation of the obtained results. The validation parameters should be selected based on the nature and purpose of the assay and the tests should be designed for the most critical steps of the assay.
The assay validation should at best serve the researcher as a tool to provide complete understanding on the characteristics and the performance of the assay. In the final analysis, the purpose of validating methods is to ensure the procurement of high quality data. After all, if the quality of data is questionable, no meaningful conclusions can be reached about the quality of the product -which will have seriously detrimental affects on stability study data reviews, process validation data reviews and annual batch reviews, to name a few. Time invested in validating analytical methods in the beginning pays big dividends in the long run.
However, until standardized methods will exist in the field of molecular biology and immunology, the demonstration of assay validity relies at this stage only on the responsibility of the researcher involved in the development of assay. Perhaps the single most important element required is a good understanding of what validation is. This understanding actually goes beyond the concept of 'requiring a minimum of three runs'. This understanding must be anchored by sufficient years of practical experience and knowledge. It will permit sound and logical decisions, even under the most intense situations.
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